Back to top
more

InMode (INMD)

(Delayed Data from NSDQ)

$17.16 USD

17.16
2,580,219

+0.59 (3.56%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $17.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide

CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.

NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod

NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.

Medtronic (MDT) Hits New 52-Week High: What's Driving It?

Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.

Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod

The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.

Here's Why You Should Retain Abbott Laboratories (ABT) Stock

Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.

Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use

According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.

Syneos Health (SYNH) New Partnership to Enhance Clinical Trials

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific

The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific

Urmimala Biswas headshot

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Will InMode (INMD) Gain on Rising Earnings Estimates?

InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

InMode (INMD) Moves 6% Higher: Will This Strength Last?

InMode (INMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

InMode (INMD) to Report Q4 Earnings: What's in the Offing?

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.

Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode

Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode

Stryker (SYK) Buys OrthoSensor to Grow in Sensor Technology

Stryker's (SYK) acquisition of OrthoSensor will help surgeons with real-time data-driven solutions and improve patient outcomes.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Market Rally

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Exagen (XGN) Looks Good: Stock Adds 9.3% in Session

Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Medtronic (MDT) MITG Shows Fast Recovery Amid COVID-19 Woes

Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.

Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD

Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD

Nalak Das headshot

5 Stocks With Recent Price Strength as Indexes Hit Record High

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Is InMode (INMD) Outperforming Other Medical Stocks This Year?

Is (INMD) Outperforming Other Medical Stocks This Year?

HEXO Catches Eye: Stock Jumps 9.4%

HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

Surging Earnings Estimates Signal Upside for InMode (INMD) Stock

InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Is InMode (INMD) Outperforming Other Medical Stocks This Year?

Is (INMD) Outperforming Other Medical Stocks This Year?

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences